题目内容
Why did Viacom demand YouTube remove clips from its website？
查看答案
搜索结果不匹配？点我反馈
更多问题
听力原文： (32)Your assignments this term will be to write two major research papers. One of the most important things about writing a research paper is giving proper credit of your resources of information. Failure to do this is called plagiarism which is a form. of intellectual dishonesty.
(33)Plagiarism is a kind of stealing or at least an unauthorized borrowing of someone else's ideas. Sometimes inexperienced students will plagiarize unintentionally, arid then he surprised when the teacher won't accept their papers, or gives them a failing grade.
The best way to avoid an unintentional plagiarizing is to be very careful in gathering your information. As you take notes on books and magazine articles about the topic you've selected, first try to assimilate the information thoroughly. (34)Secondly, write it down in your own words. This is called paraphrasing. If you do a good job of paraphrasing, you'll capture the main idea from your source without actually using any phrases from it. (34)Most of your notes should probably be paraphrases. However, occasionally you may find something you wish to quote directly in your research paper. In this case, (35) be sure that you copy the quotation precisely in your notes and enclose it in quotation marks. That way when you're finalizing your research paper, you'll be able to remember which of your notes are direct quotes and which are your own summaries of the material. You can then incorporate them appropriately and give the original author proper credit.
(33)
The investigators seriously condemned the drug firms for
Section B
Directions: There are 2 passages in this section. Each passage is followed by some questions or unfinished statements. For each of them there are four choices marked A, B, C and D. You should decide on the best choice.
Caught in a squeeze between the health needs of ageing populations on one hand and the financial crisis on the other, governments everywhere are looking for ways to slow the growth in healthcare spending. Increasingly ,they are looking to the generic-drugs(普通物) industry as a savior. In November Japan's finance ministry issued a report complaining that the country's use of generics was less than a third of that in America or Britain. In the stone month Canada's competition watchdog criticized the country's pharmacies for failing to pass on the savings made possible by the use of generic drugs. That greed, it reckoned, costs taxpayers nearly C ＄ 1 billion a year.
Then on November 28th the European Commission issued the preliminary results of its year-long probe into drug giants in the European Union. The report reached a damning, though provisional, conclusion: the drugs firms use a variety of unfair strategies to protect their expensive drugs by delaying the entry of cheaper generic opponents. Though this initial report does not carry the force of law (a final report is due early next year), it has caused much controversy. Neelie Kroes, the EU's competition commissioner, says she is ready to take legal action if the evidence allows.
One strategy the investigators criticize is the use of the "patent cluster(专利群) ". A firm keen to defend its drug due to go off-patent may file dozens or hundreds of new patents, often of dubious merit, to confuse and terrify potential copycats and maintain its monopoly. An unnamed drugs firm once took out 1,300 patents across the EU on a single drug. The report also suggests that out-of-court settlements between makers of patented drugs and generics finals may be a strategy used by the former to delay market entry by the latter.
According to EU officials, such misdeeds have delayed the arrival of generic competition and the accompanying savings. On average, the report estimates, generics arrived seven months after a patented drug lost its protection, though where the drug was a big seller the lag was four months. The report says taxpayers paid about 3 billion more than they would have had the generics gone on sale immediately.
But hang on a minute. Though many of the charges of bad behavior. leveled at the patented-drugs industry by EU investigators may well be true, the report seems to let the generics industry off the hook (钩子) too lightly. After all, if the drugs giants stand accused, in effect, of bribing opponents to delay the launch of cheap generics, shouldn't the companies that accepted those "bribes" also share the blame？
Why are governments around the world seeking ways to reduce their health-care spending？
What can we learn from the report issued by the European Commission？
微信支付 
支付宝支付